Brief Communication abstract
Nature Cell Biology 3, 1009 - 1013 (2001)
doi:10.1038/ncb1101-1009
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways
Christian Rommel1, Sue C. Bodine1, Brian A. Clarke1, Roni Rossman1, Lorna Nunez1, Trevor N. Stitt1, George D. Yancopoulos1 & David J. Glass1
Published 05 October 2001Skeletal muscle is composed of multinucleated fibres, formed after the differentiation and fusion of myoblast precursors1. Skeletal muscle atrophy and hypertrophy refer to changes in the diameter of these pre-existing muscle fibres. The prevention of atrophy would provide an obvious clinical benefit; insulin-like growth factor 1 (IGF-1) is a promising anti-atrophy agent2, 3, 4, 5 because of its ability to promote hypertrophy. However, the signalling pathways by which IGF-1 promotes hypertrophy remain unclear, with roles suggested for both the calcineurin/NFAT (nuclear factor of activated T cells) pathway6, 7 and the PtdIns-3-OH kinase (PI(3)K)/Akt pathway8. Here we employ a battery of approaches to examine these pathways during the hypertrophic response of cultured myotubes to IGF-1. We report that Akt promotes hypertrophy by activating downstream signalling pathways previously implicated in activating protein synthesis: the pathways downstream of mammalian target of rapamycin (mTOR) and the pathway activated by phosphorylating and thereby inhibiting glycogen synthase kinase 3 (GSK3). In contrast, in addition to demonstrating that calcineurin does not mediate IGF-1-induced hypertrophy, we show that IGF-1 unexpectedly acts via Akt to antagonize calcineurin signalling during myotube hypertrophy.
- Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA
Correspondence to: David J. Glass1 e-mail: david.glass@regeneron.com
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REVIEWS NEWS AND VIEWS RESEARCH |
